Lisa Ricciardi, who serves as Chief Executive Officer and President of Cognition Therapeutics Inc. (NASDAQ: CGTX), completed a purchase of the company’s common shares on April 16, 2026, totaling $10,092.
The filing shows the acquisition comprised 9,175 shares at $1.10 per share. After the purchase, Ricciardi directly owns 1,715,851 shares of Cognition Therapeutics common stock. In addition, 38,851 shares are held indirectly by her spouse, according to the same disclosure.
Market research cited alongside the transaction notes that InvestingPro analysis currently views CGTX as overvalued at present price levels. The note indicates that investors may consult a Pro Research Report available for Cognition Therapeutics and more than 1,400 other U.S. equities for a fuller analytical view.
Separately, Cognition Therapeutics reported results for the fourth quarter of 2025 and provided a full-year summary. For the year, the company recorded a net loss of $23.5 million, a decline in annual losses that the company characterized as a 30.9% improvement compared with the prior year. The company framed these results as evidence of improved operational efficiency.
On the development front, Cognition Therapeutics said it plans to advance zervimesine, its candidate for treating psychosis in dementia with Lewy bodies. The company intends to meet with the U.S. Food and Drug Administration’s Division of Psychiatry in the second quarter of 2026 to discuss a registrational plan for the treatment. That regulatory engagement follows positive data from the Phase 2 SHIMMER trial, which reportedly showed effects on neuropsychiatric inventory measurements.
Collectively, the insider purchase, the trimmed annual loss figure, and the stated regulatory engagement for zervimesine reflect ongoing financial management and clinical development activity at Cognition Therapeutics. The company’s pipeline progress and executive buying accompany an external valuation assessment that raises questions about the stock’s current market price.